Home  |  Contact

UniProtKB/Swiss-Prot P00966: Variant p.Arg100His

Argininosuccinate synthase
Gene: ASS1
Variant information

Variant position:  100
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Arginine (R) to Histidine (H) at position 100 (R100H, p.Arg100His).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to medium size and polar (H)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CTLN1.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  100
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  412
The length of the canonical sequence.

Location on the sequence:   SALYEDRYLLGTSLARPCIA  R KQVEIAQREGAKYVSHGATG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         SALYEDRYLLGTSLARPCIARKQVEIAQREGAKYVSHGATG

Mouse                         SALYEDRYLLGTSLARPCIARRQVEIAQREGAKYVSHGATG

Rat                           SALYEDRYLLGTSLARPCIARKQVEIAQREGAKYVSHGATG

Bovine                        SALYEDRYLLGTSLARPCIARKQVEIAQREGAKYVSHGATG

Chicken                       NALYEDRYMLGSALARPCIARHLVLIAQEEGARYIAHGATG

Xenopus laevis                NAIYEDRYLLGTSLARPCIAKKQVEIAKKEAAEYVSHGATG

Xenopus tropicalis            NAIYEDRYLLGTSLARPCIAKKQVEIAKKEAAEYVSHGATG

Zebrafish                     NALYEDRYLLGTSIARPCIARRQVQIAQREGAQYVSHGATG

Drosophila                    GLVYEERYLLGTSLARPCISVALMEVAREYGAKYLAHGATG

Baker's yeast                 NAVYEDVYLLGTSLARPVIAKAQIDVAKQEGCFAVSHGCTG

Fission yeast                 NAIYENVYLLGTSLARPIIARRQIQIAEKENCIAVSHGCTG

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 412 Argininosuccinate synthase
Binding site 87 – 87 Citrulline
Binding site 92 – 92 Citrulline
Binding site 119 – 119 Aspartate
Modified residue 87 – 87 Phosphotyrosine
Modified residue 112 – 112 N6-acetyllysine
Modified residue 113 – 113 Phosphotyrosine
Helix 94 – 109


Literature citations

Mutations in the human argininosuccinate synthetase (ASS1) gene, impact on patients, common changes, and structural considerations.
Diez-Fernandez C.; Ruefenacht V.; Haeberle J.;
Hum. Mutat. 38:471-484(2017)
Cited for: VARIANTS CTLN1 27-GLN--LYS-412 DEL; ILE-64; PRO-79; 97-CYS--LYS-412 DEL; CYS-100; HIS-100; ASP-111; CYS-117; 138-GLN--LYS-412 DEL; SER-157; PRO-160; 163-TYR--LYS-412 DEL; PRO-164; LYS-184; ASP-190; PRO-206; ARG-230; ILE-237; PRO-258; VAL-258; CYS-265; 275-GLY--LYS-412 DEL; THR-277; 279-ARG--LYS-412 DEL; ILE-284; PRO-290; SER-291; GLY-296; ASP-299; VAL-302; GLY-306; CYS-307; 311-GLN--LYS-412 DEL; MET-321; SER-324; VAL-324; HIS-335; PHE-341; 344-ARG--LYS-412 DEL; ARG-347; VAL-356; 357-GLN--LYS-412 DEL; ASP-359; 380-GLN--LYS-412 DEL AND PRO-389;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.